Macquarie Group Ltd. reduced its stake in REGENXBIO Inc. (NASDAQ:RGNX – Get Rating) by 0.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 149,332 shares of the biotechnology company’s stock after selling 759 shares during the period. Macquarie Group Ltd. owned approximately 0.34% of REGENXBIO worth $3,967,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. lifted its position in shares of REGENXBIO by 0.3% during the first quarter. BlackRock Inc. now owns 6,588,815 shares of the biotechnology company’s stock worth $218,683,000 after purchasing an additional 17,377 shares during the last quarter. Vanguard Group Inc. lifted its holdings in REGENXBIO by 0.4% in the first quarter. Vanguard Group Inc. now owns 4,070,462 shares of the biotechnology company’s stock worth $135,099,000 after acquiring an additional 16,496 shares during the last quarter. State Street Corp lifted its holdings in REGENXBIO by 5.6% in the second quarter. State Street Corp now owns 2,801,494 shares of the biotechnology company’s stock worth $69,197,000 after acquiring an additional 147,728 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in REGENXBIO by 16.4% in the third quarter. Dimensional Fund Advisors LP now owns 1,254,101 shares of the biotechnology company’s stock worth $33,142,000 after acquiring an additional 176,607 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in REGENXBIO by 9.7% in the second quarter. Point72 Asset Management L.P. now owns 567,500 shares of the biotechnology company’s stock worth $14,017,000 after acquiring an additional 50,233 shares during the last quarter. 80.21% of the stock is currently owned by institutional investors and hedge funds.
REGENXBIO Trading Down 2.0 %
NASDAQ RGNX opened at $22.97 on Thursday. REGENXBIO Inc. has a 12 month low of $18.69 and a 12 month high of $35.73. The company’s 50 day simple moving average is $22.88 and its 200 day simple moving average is $23.78.
Analysts Set New Price Targets
A number of equities analysts have issued reports on the stock. Chardan Capital reissued a “buy” rating and issued a $61.00 target price on shares of REGENXBIO in a report on Thursday, March 2nd. Morgan Stanley dropped their price target on shares of REGENXBIO from $50.00 to $46.00 and set an “overweight” rating on the stock in a research note on Monday. Finally, SVB Leerink dropped their price target on shares of REGENXBIO from $15.00 to $14.00 and set a “market perform” rating on the stock in a research note on Monday, January 23rd. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $40.86.
REGENXBIO, Inc is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381.
- Get a free copy of the StockNews.com research report on REGENXBIO (RGNX)
- META Platforms May See its Biggest Opening Yet for New Highs
- Penny Stock Vinco Ventures Could Be Big Winner
- Is Chip Design Specialist Synopsys A Gem Hiding In Plain Sight?
- Should You Park Some Capital with Casey’s General Stores?
- Crowdstrike Stock: While The Iron Is Hot!
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.